Merck Press Releases - EIN Presswire - Press Release Distribution Service

Published on June 6, 2014 - 12:49 GMT

Merck to Present New Clinical Data on JANUVIA® (Sitagliptin), Investigational Omarigliptin, and Real-World Data in Patients with ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, will present 13 new studies and analyses, including data for its DPP-4 inhibitor JANUVIA® (sitagliptin) and for its investigational once-weekly …

Distribution channels: Companies

Published on June 2, 2014 - 12:20 GMT

First Presentation of Data for Pembrolizumab, Merck’s Investigational Anti-PD-1 Antibody, in Patients with Previously-Untreated, ...

CHICAGO--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data evaluating pembrolizumab (MK-3475), Merck’s investigational anti-PD-1 antibody, as initial therapy in patients …

Distribution channels: Companies

Published on June 2, 2014 - 12:20 GMT

Data on Merck’s Pembrolizumab from Largest Study to Date of Investigational Anti-PD-1 Antibody in Advanced Melanoma Highlighted at ...

CHICAGO--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced new data from the company’s large ongoing Phase 1b study (KEYNOTE-001) evaluating pembrolizumab (MK-3475), Merck’s investigational anti-PD-1 …

Distribution channels: Companies

Published on June 1, 2014 - 13:37 GMT

First Presentation of Early Data for Pembrolizumab (MK-3475), Merck’s Investigational Anti-PD-1 Antibody, in Advanced Head and ...

CHICAGO--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of early findings from a Phase 1b study (KEYNOTE-012) evaluating pembrolizumab (MK-3475), Merck’s investigational anti-PD- …

Distribution channels: Companies

Published on May 27, 2014 - 16:54 GMT

Merck Announces Third-Quarter 2014 Dividend

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.44 per share of the company’s common stock for the third …

Distribution channels: Companies

Published on May 19, 2014 - 21:28 GMT

Merck and Endocyte Announce Withdrawal of Conditional Marketing Authorization Applications for Vintafolide and Companion Imaging ...

WHITEHOUSE STATION, N.J. WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Endocyte, Inc. (NASDAQ:ECYT), today announced the withdrawal of conditional marketing authorization applications (CMA) …

Distribution channels: Companies

Published on May 14, 2014 - 14:00 GMT

The American College of Endocrinology & Merck Urge Patients with Type 2 Diabetes to Work with Their Doctor to Get to Their Blood ...

Today, the American College of Endocrinology (ACE), with support from Merck, known as MSD outside the United States and Canada, has launched the new Blood Sugar Basics: Get to Your Goals program to help educate the nearly 26 million Americans living with …

Distribution channels: Companies

Published on May 14, 2014 - 12:14 GMT

Merck’s Investigational Anti-PD1 Antibody, MK-3475, Active in Three Different Tumor Types: New Data to be Presented at the 2014 ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new data for the company’s investigational anti-PD-1 antibody, MK-3475, in advanced melanoma, non-small cell lung cancer ( …

Distribution channels: Companies

Published on May 13, 2014 - 06:28 GMT

Merck Signs Sale Agreement with Santen for Merck’s Ophthalmology Products in Japan and Key Markets in Europe and Asia Pacific

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that it signed an agreement for Santen Pharmaceutical Co., Ltd. (Santen) to purchase Merck’s ophthalmology products, COSOPT® ( …

Distribution channels: Companies

Published on May 12, 2014 - 12:32 GMT

FDA Approves ZONTIVITY™ (vorapaxar), First-in-Class PAR-1 Antagonist, for the Reduction of Thrombotic Cardiovascular Events in ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved ZONTIVITY™ (vorapaxar) for the reduction of thrombotic …

Distribution channels: Companies

Published on May 8, 2014 - 13:17 GMT

AiCuris and Merck Announce Publication in New England Journal of Medicine of Phase 2 Clinical Trial Results of Investigational ...

WUPPERTAL, Germany WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--AiCuris and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the publication of results from a Phase 2 clinical trial evaluating the safety and efficacy of …

Distribution channels: Companies

Published on May 6, 2014 - 13:53 GMT

Merck Announces FDA Acceptance for Review of MK-3475 Biologics License Application for Advanced Melanoma

BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for MK-3475, Merck’s …

Distribution channels: Companies

Published on May 6, 2014 - 13:53 GMT

Merck Highlights Progress on Its Strategic Initiative to Sharpen Commercial and R&D Focus; Drive Growth and Productivity

BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today is hosting an Investor Briefing at the company’s research facility in Boston. The briefing is also available via webcast at www.merck.com starting at 9:00 a …

Distribution channels: Companies

Published on May 2, 2014 - 12:51 GMT

Merck and Endocyte Announce Independent DSMB Recommends Vintafolide PROCEED Phase 3 Trial Be Stopped for Futility Following ...

WHITEHOUSE STATION, N.J. WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Endocyte, Inc. (NASDAQ:ECYT), today announced that the Data Safety Monitoring Board (DSMB) of the PROCEED trial has …

Distribution channels: Companies

Published on April 28, 2014 - 12:25 GMT

Merck to Hold Investor Briefing at Boston Research Facility

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, will hold an Investor Briefing on Tuesday, May 6, 2014 starting at 9:00 a.m. EDT at its research facility in Boston, MA. During the event, …

Distribution channels: Companies

Published on April 23, 2014 - 15:27 GMT

Merck and Award-Winning Actress S. Epatha Merkerson Challenge Americans with Type 2 Diabetes to Get to Their Goals

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced it is teaming up with Emmy and Golden Globe-winning actress S. Epatha Merkerson on America’s Diabetes Challenge: Get to Your Goals, an educational program intended to …

Distribution channels: Companies

Published on April 17, 2014 - 23:50 GMT

FDA Approves Merck’s RAGWITEK™ (Short Ragweed Pollen Allergen Extract) Sublingual Tablet as Immunotherapy to Treat Short Ragweed ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved RAGWITEK™ (Short Ragweed Pollen Allergen Extract) Tablet for …

Distribution channels: Companies

Published on April 14, 2014 - 23:03 GMT

FDA Approves Merck’s GRASTEK® (Timothy Grass Pollen Allergen Extract) Sublingual Tablet as Immunotherapy to Treat Grass Pollen-...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved GRASTEK® (Timothy Grass Pollen Allergen Extract) Tablet for …

Distribution channels: Companies

Published on April 11, 2014 - 06:14 GMT

Merck’s Investigational Chronic Hepatitis C Combination Therapy MK-5172/MK-8742 Demonstrates Antiviral Activity in Hard-to-Cure ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced interim results from the ongoing C-WORTHy study, a multi-arm Phase 2 clinical trial evaluating the efficacy and safety of an …

Distribution channels: Companies

Published on April 10, 2014 - 06:07 GMT

Merck Announces Results from Studies Evaluating Investigational Hepatitis C Treatments, MK-5172 and MK-8742, in Treatment-Naïve ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced additional data from the ongoing C-WORTHy study, a multi-arm Phase 2 clinical trial evaluating the efficacy and safety of a …

Distribution channels: Companies